Abstract
Acute Myeloid Leukemia (AML) is the most prevalent bone marrow cancer in Brazil, presenting a significant and challenging health issue due to its broad clinical and molecular variability. This makes precise risk stratification essential for guiding appropriate treatment. Traditional therapies, which combine cytarabine and anthracyclines, remain predominant. However, the heterogeneity of A…